Genprex, Inc. (GNPX)
Oxford Ledge is still expanding full research coverage of GNPX. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Clinical-stage gene therapy company developing tumor suppressor and diabetes cell-transformation therapies using lipid nanoparticle delivery.
SEC filings
- 8-K 3.03; Amendments to articles or bylaws; Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-07-14
- 8-K Other material event; Financial statements and exhibits 2026-06-22
- 8-K Departure/election of directors or officers; Shareholder vote results; Financial statements and exhibits 2026-06-18
- 8-K Delisting / transfer of listing; Other material event; Financial statements and exhibits 2026-06-12
- 8-K Other material event; Financial statements and exhibits 2026-05-26
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for GNPX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open GNPX in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.